Search

Your search keyword '"Wang, Chao"' showing total 33,642 results
Start Over Author "Wang, Chao" Language english
33,642 results on '"Wang, Chao"'

64. Impact of the COVID-19 Pandemic on Partner Relationships and Sexual and Reproductive Health: Cross-Sectional, Online Survey Study

Author

Li, Guanjian, Tang, Dongdong, Song, Bing, Wang, Chao, Qunshan, Shen, Xu, Chuan, Geng, Hao, Wu, Huan, He, Xiaojin, and Cao, Yunxia

Subjects
Computer applications to medicine. Medical informatics, R858-859.7, Public aspects of medicine, RA1-1270
Abstract

BackgroundIn the past few months, the coronavirus disease (COVID-19) pandemic has caused extensive economic and social damage. ObjectiveThe purpose of this study was to assess the impact of COVID-19–related measures on partner relationships and sexual and reproductive health in China. MethodsFrom May 1 to 5, 2020, 3500 young Chinese individuals were recruited through WeChat or Weibo to participate in a survey to obtain information on sexual and reproductive health (eg, sexual desire, frequency of sexual intercourse, sexual satisfaction, etc). The questionnaire also collected demographic data (eg, age, race, education, current financial status, sexual orientation, relationship status, etc). ResultsIn total, 967 participants were included in the sexual health analysis. Due to the COVID-19 pandemic and related containment measures, 22% of participants (n=212) reported a decrease in sexual desire; 41% (n=396) experienced a decrease in the sexual intercourse frequency; 30% (n=291) reported an increase in the frequency of masturbation; 20% (n=192) reported a decrease in alcohol consumption before or during sexual activities, and 31% (n=298) reported a deterioration in partner relationships during the pandemic. The logistic regression analysis indicated that the following influenced partner relationships: accommodations during the pandemic (P=.046; odds ratio [OR] 0.59; 95% CI 0.30-0.86); exclusive relationship status (yes or no) (P

Published
2020
Full Text
View/download PDF

65. Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial

Author

Merkel, Peter A, Jayne, David R, Wang, Chao, Hillson, Jan, and Bekker, Pirow

Subjects
Medicine, Computer applications to medicine. Medical informatics, R858-859.7
Abstract

BackgroundAntineutrophil cytoplasmic antibody (ANCA)–associated vasculitis is a serious, often life-threatening disease. In new-onset disease or a relapse, the standard treatment is immunosuppressive therapy with glucocorticoids; these therapies are associated with substantial short- and long-term toxicity. Complement component 5a (C5a) binding to C5a receptor (C5aR) may play a central role in the pathogenesis of ANCA-associated vasculitis. Avacopan is a novel, orally bioavailable, and highly selective antagonist of human C5aR. Avacopan does not interfere with the production of C5b or the membrane attack complex (ie, terminal complement complex) and does not block C5a binding to a second receptor, C5L2 (also called C5aR2), shown to be protective in antimyeloperoxidase glomerulonephritis. This trial will evaluate if avacopan replaces the need for chronic glucocorticoids in the treatment of ANCA-associated vasculitis. ObjectiveThe aim of this study is to determine the proportions of patients in remission at week 26 and with sustained remission at week 52, defined as Birmingham Vasculitis Activity Score=0, and not taking glucocorticoids within the 4 weeks before week 26 and week 52, respectively. MethodsThe Avacopan Development in Vasculitis to Obtain Corticosteroid elimination and Therapeutic Efficacy study is a randomized, double-blind, active-comparator (prednisone), 2-arm study evaluating the safety and efficacy of avacopan versus prednisone, administered in combination with other immunosuppressive therapy. Eligible subjects will have active disease requiring induction of remission. Subjects are stratified based on the type of immunosuppressive therapy, ANCA subtype, and new or relapsing disease. Target sample size is 300 patients, enrolled at over 200 sites globally. All authors and local ethics committees approved the study design. All patients will provide informed consent. ResultsEnrollment of patients was completed in Q4 2018. Topline results are anticipated to be published by Q3 2020. ConclusionsResults will be released irrespective of whether the findings are positive or negative. Trial RegistrationClinicalTrials.gov NCT02994927; https://clinicaltrials.gov/ct2/show/NCT02994927 International Registered Report Identifier (IRRID)DERR1-10.2196/16664

Published
2020
Full Text
View/download PDF

78. Hollow Multishelled Structure: Synthesis Chemistry and Application

Author

Mao, Dan, Wang, Chao, Li, Wei, Zhou, Liang, Liu, Jian, Zheng, Zijian, Zhao, Yong, Cao, An-min, Wang, Shutao, Huang, Jiaxing, Huo, Fengwei, Chen, Hongyu, Mai, Liqiang, Yu, Ranbo, Wang, Lianzhou, Lu, Yunfeng, Yu, Chengzhong, Yang, Qihua, Yang, Zhenzhong, Zeng, Hua Chun, Zhao, Huijun, Tang, Zhiyong, Zhao, Dongyuan, and Wang, Dan

Published
2024
Full Text
View/download PDF

100. Fibration of powdery materials

Author

Wang, Hanwei, Zeng, Cheng, Wang, Chao, Fu, Jinzhou, Li, Yingying, Yang, Yushan, Du, Zhichen, Tao, Guangming, Sun, Qingfeng, Zhai, Tianyou, and Li, Huiqiao

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results